• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,550.25 918.60
( 1.20%)
Global Indices
Nasdaq
47,930.49 -276.32
(-0.57%)
Dow Jones
6,837.38 -8.28
(-0.12%)
Hang Seng
56,916.27 1,020.95
(1.83%)
Nikkei 225
10,596.33 -7.15
(-0.07%)
Forex
USD-INR
92.50 0.06
(0.07%)
EUR-INR
108.05 0.09
(0.08%)
GBP-INR
124.08 0.03
(0.03%)
JPY-INR
0.58 0.00
(-0.25%)

EQUITY - MARKET SCREENER

Groarc Industries India Ltd
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
532315
INE042B01012
18.9854513
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
0
12.28
EPS(TTM)
Face Value()
Div & Yield %
0
10
0
 

Lupin receives USFDA approval for Dapagliflozin and Metformin Hydrochloride XR Tablets
Apr 08,2026
Lupin today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg. The company also received tentative approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 2.5 mg/1,000 mg.

The U.S. FDA has approved Lupin's Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets as bioequivalent to Xigduo® XR for the indications in the approved labeling.